Vertex Pharmaceuticals Incorporated (VRTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
50 Northern Avenue
Boston, MA 02210
United States of America (the)
Phone
617 341 6100
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6100
First IPO Date
July 24, 1991
| Name | Title | Pay | Year Born |
| Reshma Kewalramani FASN | Chief Executive Officer, President & Director | 6.14M | 1973 |
| Amit K. Sachdev | Executive Vice President & Chief Patient and External Affairs Officer | 1.88M | 1968 |
| Ourania Tatsis | Executive Vice President and Chief Regulatory & Quality Officer | 2.07M | 1970 |
| Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 2.27M | 1963 |
| Mark Bunnage D.Phil | Executive Vice President & Chief Scientific Officer | 2.39M | 1969 |
| Charles F. Wagner Jr. | Executive Vice President, Chief Operating Officer & Chief Financial Officer | 2.99M | 1968 |
| Duncan J. McKechnie | Chief Commercial Officer, Head of North America Commercial & Executive VP | 0 | 1969 |
| Jeffrey Marc Leiden | Executive Chairman | 0 | 1956 |
| Kristen C. Ambrose | Senior Vice President & Chief Accounting Officer | 0 | 1977 |
| Miroslava Atanassova Minkova | Executive Director of Investor Relations | 0 | N/A |
| Felicia Pagliuca | Senior Vice President of Cell & Genetic Therapy Research | 0 | N/A |
| Joy Liu | EVP, Chief Legal Officer & Corporate Secretary | 0 | 1978 |
| Edward Morrow Atkinson | EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | 0 | 1966 |
| Susie Lisa | Senior Vice President of Investor Relations | 0 | N/A |
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.